Mozobil (Plerixafor)
CXCR4 Antagonist for Haematopoietic Stem Cell Mobilisation
Quick Facts About Mozobil
Key Takeaways About Mozobil (Plerixafor)
- Used alongside G-CSF: Mozobil is always administered in combination with G-CSF to maximise mobilisation of stem cells from bone marrow into the bloodstream for collection
- For poor mobilisers: Primarily indicated for patients with lymphoma or multiple myeloma who cannot mobilise enough stem cells with G-CSF alone for autologous transplantation
- Rapid onset of action: Stem cell mobilisation begins within hours of injection, with peak CD34+ cell counts occurring 9–14 hours after the subcutaneous dose
- Short treatment course: Treatment typically lasts 2–4 days (maximum 7 days) until sufficient stem cells have been collected
- Administered by healthcare professionals: Given as a subcutaneous injection in a hospital or clinical setting, 6–11 hours before each apheresis session
What Is Mozobil and What Is It Used For?
Mozobil (plerixafor) is a CXCR4 chemokine receptor antagonist that mobilises haematopoietic stem cells from the bone marrow into the peripheral blood. It is used in combination with G-CSF to facilitate stem cell collection (apheresis) before autologous stem cell transplantation in patients with lymphoma, multiple myeloma, or certain paediatric cancers.
Haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for various haematological malignancies, including non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma. The procedure involves collecting the patient's own stem cells (autologous transplant), administering high-dose chemotherapy to destroy cancerous cells, and then reinfusing the collected stem cells to reconstitute the bone marrow and restore normal blood cell production. A critical step in this process is mobilisation – the process of moving enough stem cells from the bone marrow into the peripheral blood so they can be collected.
Traditionally, G-CSF (granulocyte colony-stimulating factor, also known as filgrastim or lenograstim) has been the primary agent used for stem cell mobilisation. G-CSF stimulates the bone marrow to produce more white blood cells and stem cells, gradually releasing them into the bloodstream over several days. However, a significant proportion of patients – estimated at 15–40% depending on the population – fail to mobilise adequate numbers of CD34+ stem cells with G-CSF alone. These patients are termed "poor mobilisers" and may face delays in transplantation or require multiple apheresis sessions.
Mozobil addresses this challenge through a distinct and complementary mechanism of action. Plerixafor, the active substance in Mozobil, is a selective, reversible antagonist of the CXCR4 chemokine receptor. Under normal physiological conditions, the chemokine stromal cell-derived factor-1 alpha (SDF-1α, also known as CXCL12) binds to the CXCR4 receptor on the surface of haematopoietic stem cells, effectively anchoring them within the bone marrow microenvironment. By blocking this CXCR4/SDF-1α interaction, plerixafor releases stem cells from their bone marrow niche, causing a rapid and significant increase in circulating CD34+ cells within hours of injection.
When used together, G-CSF and plerixafor act synergistically: G-CSF expands the stem cell pool and initiates gradual mobilisation over 4–5 days, while plerixafor provides an additional acute mobilisation boost. Clinical trials have demonstrated that the combination of G-CSF plus plerixafor results in significantly higher CD34+ cell yields compared to G-CSF alone, enabling more patients to reach the target cell dose needed for successful transplantation.
Approved Indications
Mozobil is approved for the following indications, always in combination with G-CSF:
- Adults with lymphoma or multiple myeloma: To enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients who are poor mobilisers
- Children aged 1 year to under 18 years: With lymphoma or solid tumours, to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation
Mozobil was first approved by the US Food and Drug Administration (FDA) in December 2008 and by the European Medicines Agency (EMA) in July 2009. It was developed by AnorMED and later acquired by Genzyme (now part of Sanofi). It represented a significant advance in stem cell transplantation, as it was the first CXCR4 antagonist approved for clinical use, offering a solution for patients who previously could not proceed to transplantation due to insufficient stem cell mobilisation.
What Should You Know Before Using Mozobil?
Before receiving Mozobil, inform your doctor about all medical conditions, especially heart problems, kidney disease, high white blood cell counts, low platelet counts, or a history of leukaemia. Mozobil should not be used in patients with leukaemia or known hypersensitivity to plerixafor.
Contraindications
You should not receive Mozobil if any of the following apply:
- Hypersensitivity to plerixafor or any of the excipients (sodium chloride, hydrochloric acid, sodium hydroxide, or water for injections) – allergic reactions including anaphylaxis have been reported
- Leukaemia (cancer of the blood or bone marrow): Mozobil should not be used for stem cell mobilisation in patients with leukaemia due to the risk of mobilising leukaemic cells into the peripheral blood, which could potentially increase the number of circulating tumour cells
Warnings and Precautions
Talk to your doctor or haematologist before receiving Mozobil if you have or have had any of the following conditions:
- Cardiovascular problems: Patients with cardiac risk factors should be monitored closely. In clinical studies, myocardial infarction (heart attack) has been reported uncommonly in patients receiving Mozobil in combination with G-CSF who had pre-existing cardiac risk factors. Inform your doctor immediately if you experience chest pain, shortness of breath, or any cardiac symptoms during treatment
- Kidney problems: Plerixafor is primarily excreted by the kidneys. If you have moderate to severe renal impairment (creatinine clearance ≤50 ml/min), your doctor will reduce the dose by one-third. There is limited clinical experience in patients with severe renal impairment or those on dialysis
- High white blood cell count (leukocytosis): Both G-CSF and Mozobil cause an increase in circulating white blood cells. Your doctor will monitor your blood counts regularly throughout treatment. If your white blood cell count exceeds 100 × 109/L, your doctor may consider discontinuing Mozobil
- Low platelet count (thrombocytopenia): Thrombocytopenia has been associated with apheresis and with the use of Mozobil. Platelet counts should be monitored in all patients receiving Mozobil
- Spleen enlargement: G-CSF alone and in combination with Mozobil has been associated with splenic enlargement, and rare cases of splenic rupture have been reported. Inform your doctor immediately if you experience pain in the upper left abdomen or left shoulder tip, as these may be signs of splenic problems
- History of fainting or vasovagal reactions: If you have previously felt faint, dizzy, or have fainted during or after injections, inform your healthcare team so appropriate precautions can be taken
Rash, swelling around the eyes, shortness of breath or difficulty breathing, lightheadedness when standing or sitting, or feeling faint or actually fainting shortly after receiving Mozobil. These may be signs of a serious allergic reaction (anaphylaxis). Also seek urgent medical attention for pain in the upper left abdomen or left shoulder, which may indicate splenic enlargement or rupture.
Pregnancy and Breastfeeding
Mozobil should not be used during pregnancy. There is no clinical experience with plerixafor in pregnant women, and animal reproductive studies have demonstrated adverse effects on the developing foetus, including teratogenicity and embryotoxicity. Women of childbearing potential must use effective contraception during treatment with Mozobil.
Breastfeeding should be discontinued during treatment with Mozobil. It is not known whether plerixafor or its metabolites are excreted in human breast milk. Given the potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue Mozobil treatment, taking into account the importance of the treatment to the mother.
Driving and Operating Machinery
Mozobil can cause dizziness and fatigue. Patients who experience these symptoms should avoid driving vehicles or operating machinery. Given that Mozobil is administered in a hospital or clinical setting as part of a stem cell mobilisation programme, patients are typically under medical supervision and are unlikely to need to drive immediately after receiving the injection.
Sodium Content
This medicine contains less than 1 mmol sodium (23 mg) per dose, which means it is essentially sodium-free. This information is relevant for patients on a controlled sodium diet.
How Does Mozobil Interact with Other Drugs?
Mozobil has relatively few known drug interactions because it is not metabolised by cytochrome P450 enzymes. However, it is always used in combination with G-CSF, and the interaction between these two drugs is central to its therapeutic effect. Tell your doctor about all medicines you are currently taking.
Plerixafor is not significantly metabolised by hepatic cytochrome P450 enzymes (CYP450 system) and is primarily excreted unchanged by the kidneys. This pharmacokinetic profile means that clinically significant drug–drug interactions mediated through hepatic enzyme inhibition or induction are unlikely. However, certain considerations remain important.
Because plerixafor is eliminated primarily via renal excretion, drugs that significantly affect kidney function could potentially alter plerixafor clearance. Concurrent use of nephrotoxic agents should be approached with caution, and renal function should be monitored. Additionally, since both G-CSF and plerixafor increase white blood cell counts, the combination can lead to significant leukocytosis, which requires monitoring.
Key Drug Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| G-CSF (Filgrastim, Lenograstim) | Colony-stimulating factor | Synergistic enhancement of stem cell mobilisation; additive leukocytosis | Required combination – this is the intended clinical use. Monitor WBC counts regularly |
| Nephrotoxic agents | Various (aminoglycosides, NSAIDs, etc.) | May reduce renal clearance of plerixafor, increasing drug exposure | Monitor renal function; dose adjustment of plerixafor may be needed |
| Chemotherapy agents | Antineoplastic drugs | Chemo-mobilisation regimens may be used alongside G-CSF and plerixafor | Timing must be carefully coordinated by the transplant team |
| Heparin | Anticoagulant | Used during apheresis; combined with plerixafor-induced thrombocytopenia risk | Monitor platelet counts closely during apheresis sessions |
No formal drug interaction studies have been conducted with plerixafor beyond its mandatory combination with G-CSF. In vitro studies indicate that plerixafor is neither a substrate nor an inhibitor of CYP450 enzymes and is not a substrate for P-glycoprotein. The primary route of elimination is renal, with approximately 70% of the dose excreted unchanged in urine within 24 hours. Therefore, drugs that compete for renal tubular secretion could theoretically interact with plerixafor, though this has not been observed clinically.
What Is the Correct Dosage of Mozobil?
The recommended dose of Mozobil for adults is either a fixed dose of 20 mg or a weight-based dose of 0.24 mg/kg body weight per day, given as a subcutaneous injection 6–11 hours before apheresis. The dose is reduced in patients with renal impairment. Treatment typically lasts 2–4 consecutive days.
Mozobil is always used as part of a mobilisation regimen in combination with G-CSF. The G-CSF treatment is started first, typically 4–5 days before the first dose of Mozobil, to begin expanding and mobilising the stem cell population. Mozobil is then added to provide an additional mobilisation boost before each apheresis session.
Adults
Standard Adult Dosage
Dose: 20 mg (fixed dose) or 0.24 mg/kg body weight per day
Route: Subcutaneous injection
Timing: 6 to 11 hours before the start of each apheresis session
Duration: 2–4 consecutive days (up to a maximum of 7 days)
Notes: The patient's body weight should be measured within one week before the first dose. Treatment continues until sufficient stem cells have been collected for transplantation.
Renal Impairment (CrCl ≤50 ml/min)
Dose: Reduced to 0.16 mg/kg body weight per day (one-third reduction)
Route: Subcutaneous injection
Notes: The dose should not exceed 27 mg/day regardless of body weight. Limited data are available for patients with severe renal impairment (CrCl <20 ml/min) or those on haemodialysis.
Children (1 Year to Under 18 Years)
Paediatric Dosage
Dose: 0.24 mg/kg body weight per day
Route: Subcutaneous injection
Timing: 6 to 11 hours before apheresis
Duration: 2–4 consecutive days (up to 7 days)
Notes: Safety and efficacy have not been established in children below 1 year of age. Paediatric dosing is weight-based and should be determined by the treating specialist.
Elderly Patients
No specific dose adjustment is recommended for elderly patients solely based on age. However, renal function declines with age, and dose adjustments should be made according to creatinine clearance. Elderly patients are also more likely to have pre-existing cardiac conditions, and cardiovascular monitoring is particularly important in this population.
How Is Mozobil Given?
Mozobil is administered by a healthcare professional (doctor or nurse) as a subcutaneous injection (injected under the skin). The injection is typically given in the upper arm, abdomen, or thigh. The following steps outline the usual mobilisation process:
- Days 1–4 (approximately): G-CSF is started at the standard mobilisation dose (typically 10 µg/kg/day) to begin stem cell expansion and initial mobilisation
- Evening of Day 4 (approximately): Mozobil is given as a subcutaneous injection, 6–11 hours before the planned apheresis session on Day 5
- Day 5 morning: Apheresis is performed to collect stem cells from the peripheral blood
- Repeat: Steps 2–3 are repeated daily until sufficient stem cells have been collected (target is typically ≥2 × 106 CD34+ cells/kg for a single transplant, or ≥5 × 106 CD34+ cells/kg for optimal outcomes)
Overdose
There is limited clinical experience with overdose of plerixafor. In a dose-escalation study in healthy volunteers, doses up to 0.48 mg/kg were investigated. The dose-limiting adverse effects at higher doses included gastrointestinal symptoms (nausea, vomiting, diarrhoea), vasovagal reactions, and orthostatic hypotension. There is no specific antidote for plerixafor overdose. If overdose occurs, the patient should be monitored for signs and symptoms of adverse reactions and given appropriate supportive treatment.
| Patient Group | Dose | Route | Special Considerations |
|---|---|---|---|
| Adults (normal renal function) | 20 mg or 0.24 mg/kg/day | Subcutaneous | Weigh patient within 1 week of first dose |
| Adults (CrCl ≤50 ml/min) | 0.16 mg/kg/day | Subcutaneous | Max 27 mg/day; monitor renal function |
| Children (1–17 years) | 0.24 mg/kg/day | Subcutaneous | Weight-based dosing; specialist supervision |
| Elderly | As per adult dosing | Subcutaneous | Adjust based on renal function; cardiac monitoring |
What Are the Side Effects of Mozobil?
The most common side effects of Mozobil include gastrointestinal symptoms (diarrhoea, nausea, vomiting), injection site reactions, headache, dizziness, and fatigue. Serious but uncommon side effects include allergic reactions (including anaphylaxis) and myocardial infarction in patients with cardiac risk factors.
Like all medicines, Mozobil can cause side effects, although not everybody gets them. Most side effects observed during clinical trials were mild to moderate in severity and of short duration. It is important to remember that Mozobil is always used together with G-CSF, so some side effects may be attributable to G-CSF, to the underlying disease, or to the apheresis procedure itself rather than to plerixafor specifically.
The side effect profile of Mozobil has been well characterised in pivotal Phase III clinical trials (AMD3100-3101 and AMD3100-3102) involving patients with non-Hodgkin lymphoma and multiple myeloma, as well as in post-marketing surveillance. The following frequency classifications are based on these data.
Very Common (affects more than 1 in 10 people)
- Diarrhoea
- Nausea
- Injection site reactions (redness, irritation, pain, swelling)
- Anaemia / low red blood cell count (particularly in children)
Common (affects up to 1 in 10 people)
- Headache
- Dizziness
- Fatigue and malaise
- Insomnia and sleep disturbances
- Flatulence (gas)
- Constipation
- Dyspepsia (indigestion)
- Vomiting
- Abdominal pain, bloating, or discomfort
- Dry mouth
- Oral hypoaesthesia (numbness around the mouth)
- Hyperhidrosis (excessive sweating)
- Generalised erythema (skin redness)
- Arthralgia (joint pain)
- Musculoskeletal pain and bone pain
Uncommon (affects up to 1 in 100 people)
- Allergic reactions (skin rash, urticaria, periorbital swelling)
- Anaphylactic reactions, including anaphylactic shock
- Abnormal dreams and nightmares
- Myocardial infarction (in patients with cardiac risk factors)
Rare and Post-Marketing Reports
- Severe gastrointestinal events (severe diarrhoea, severe vomiting)
- Splenic enlargement (splenomegaly)
- Splenic rupture (very rare, reported with G-CSF)
- Vasovagal reactions
- Dyspnoea (shortness of breath) and hypoxia
Cardiac Risk
In clinical studies, patients with pre-existing cardiovascular risk factors experienced uncommon cases of myocardial infarction after receiving Mozobil in combination with G-CSF. The causal relationship has not been definitively established, as these patients had significant underlying cardiovascular disease and were also receiving G-CSF. Nevertheless, patients with known cardiac risk factors should be carefully evaluated before starting Mozobil and monitored throughout treatment. Seek immediate medical attention if you experience chest pain, tightness, or pressure, shortness of breath, pain radiating to the arm, jaw, or back, or sudden onset of nausea and cold sweats.
Leukocytosis (Elevated White Blood Cell Count)
An increase in white blood cell count is an expected pharmacological effect of both G-CSF and Mozobil. Your doctor will perform regular blood tests to monitor your white blood cell count throughout the mobilisation process. In most cases, the leukocytosis is transient and resolves after completion of mobilisation. However, if counts become excessively high (>100 × 109/L), your doctor may discontinue treatment.
Paraesthesia and Numbness
Tingling sensations (paraesthesia) and numbness are common in patients undergoing cancer treatment and stem cell mobilisation. Approximately one in five patients may experience these symptoms. Studies suggest that this frequency is not significantly increased by the addition of Mozobil to G-CSF, indicating that paraesthesia is likely related to the underlying disease or prior chemotherapy rather than to plerixafor specifically.
It is important to report suspected side effects after a medicine has been authorised. This enables ongoing monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients can report suspected adverse reactions through their national reporting system, such as the FDA MedWatch programme (US), the MHRA Yellow Card Scheme (UK), or the EMA EudraVigilance system (EU).
How Should You Store Mozobil?
Mozobil should be stored at room temperature with no special storage conditions required. Keep out of reach of children and do not use after the expiry date. Once the vial has been opened, the solution should be used immediately.
The following storage guidelines apply to Mozobil solution for injection:
- Temperature: No special temperature storage conditions are required. Store at room temperature
- Light protection: No special light protection requirements
- After opening: The solution should be used immediately once the vial has been opened. Mozobil does not contain preservatives, so any unused solution must be discarded
- Expiry date: Do not use Mozobil after the expiry date stated on the carton and vial label. The expiry date refers to the last day of that month
- Appearance: Before use, the solution should be visually inspected. It should be clear, colourless to slightly yellow, and free from visible particles. Do not use if the solution is discoloured, cloudy, or contains particles
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help to protect the environment
- Keep out of reach of children: Store this medicine out of the sight and reach of children
What Does Mozobil Contain?
Each vial of Mozobil contains 24 mg of plerixafor in 1.2 ml of solution (concentration: 20 mg/ml). The other ingredients are sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections.
Active Ingredient
The active substance is plerixafor. Each millilitre of solution for injection contains 20 mg of plerixafor. Each single-use glass vial contains 1.2 ml of solution, providing a total of 24 mg of plerixafor per vial. Plerixafor is a bicyclam compound (chemical name: 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]) with a molecular weight of 502.78 g/mol.
Excipients (Inactive Ingredients)
- Sodium chloride: Used to make the solution isotonic (compatible with body fluids)
- Hydrochloric acid (concentrated): Used for pH adjustment
- Sodium hydroxide: Used for pH adjustment
- Water for injections: Solvent
Appearance and Packaging
Mozobil is supplied as a clear, colourless to slightly yellow solution for injection in a Type I glass vial with a latex-free rubber stopper sealed with an aluminium flip-off cap. Each carton contains one single-use vial containing 1.2 ml of solution. The vial is designed for single use only; any unused portion must be discarded.
Manufacturer
Mozobil is manufactured by Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland. The marketing authorisation holder is Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands. Generic versions are also available from other pharmaceutical companies including Teva and Accord Healthcare.
Frequently Asked Questions About Mozobil
Mozobil is used in combination with G-CSF to mobilise haematopoietic (blood-forming) stem cells from the bone marrow into the peripheral bloodstream. These stem cells are then collected through a process called apheresis and stored for later use in autologous stem cell transplantation. It is indicated for adults with lymphoma or multiple myeloma who are poor mobilisers, and for children aged 1 to under 18 years with lymphoma or solid tumours.
Mozobil works by blocking the CXCR4 receptor on haematopoietic stem cells. Under normal conditions, a protein called SDF-1α (CXCL12) binds to this receptor and anchors stem cells within the bone marrow. By blocking this interaction, Mozobil allows the stem cells to be released into the bloodstream, where they can be collected. When used with G-CSF, which has already expanded the stem cell pool over several days, Mozobil provides an additional surge of stem cells into the blood.
Mozobil and G-CSF work through different but complementary mechanisms. G-CSF stimulates the bone marrow to produce more stem cells and gradually releases them over several days. Mozobil then provides a rapid additional release by blocking the receptor that holds stem cells in the bone marrow. Together, they achieve significantly higher stem cell yields than either agent alone, which is critical for ensuring that enough cells are collected for a successful transplant. Mozobil alone would release stem cells already present in the bone marrow, but without G-CSF to expand the pool first, the yield would be insufficient.
Mozobil is typically administered by healthcare professionals in a hospital or clinical setting, as it is part of a complex stem cell mobilisation and collection programme that requires close medical supervision, including apheresis procedures and blood monitoring. However, in some healthcare systems, patients may be trained to self-administer the subcutaneous injection at home under the guidance of their transplant team, particularly if they are experienced with subcutaneous injections. This decision is made on an individual basis by the treating physician.
If insufficient stem cells are collected despite treatment with G-CSF and Mozobil, the collection attempt may be extended for additional days (up to a maximum of 7 days of Mozobil). If the target CD34+ cell dose still cannot be achieved, the transplant team will discuss alternative strategies, which may include additional mobilisation attempts at a later date, bone marrow harvest under general anaesthesia, or reassessment of the overall treatment plan. The transplant team will make this decision based on the individual patient's clinical situation.
Mozobil can be used in patients with kidney problems, but the dose must be adjusted. Since plerixafor is primarily excreted by the kidneys, patients with moderate to severe renal impairment (creatinine clearance ≤50 ml/min) should receive a reduced dose of 0.16 mg/kg/day instead of the standard 0.24 mg/kg/day. There is limited experience in patients with very severe kidney disease or those on dialysis, so careful evaluation by the transplant team is needed in these cases.
References
- European Medicines Agency (EMA). Mozobil (plerixafor) – Summary of Product Characteristics. Last updated 2024. Available at: EMA product information.
- US Food and Drug Administration (FDA). Mozobil (plerixafor injection) – Prescribing Information. Sanofi Genzyme, 2023.
- DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–5726.
- DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767–4773.
- Duarte RF, Chabannon C, Bernasconi P, et al. Plerixafor for stem cell mobilisation: the European perspective. Bone Marrow Transplant. 2018;53(5):543–551.
- National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance TA465: Plerixafor for stem cell mobilisation in lymphoma and multiple myeloma. 2017.
- Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.
- Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31–40.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- European Society for Blood and Marrow Transplantation (EBMT). EBMT Handbook: Haematopoietic Stem Cell Transplantation and Cellular Therapies. 8th Edition, 2024.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in haematology, oncology, clinical pharmacology, and stem cell transplantation.
iMedic Medical Editorial Team – specialists in haematology and clinical pharmacology with experience in stem cell transplantation and supportive care.
iMedic Medical Review Board – independent panel of medical experts who verify accuracy, completeness, and adherence to international guidelines (EBMT, ASBMT, NICE, EMA, FDA).
This article follows the GRADE evidence framework and is based on systematic reviews, randomised controlled trials, and international clinical guidelines. All content is independently produced with no commercial funding or pharmaceutical industry sponsorship. Last reviewed: .